The Basser Center's Young Leadership Council recently hosted a storytelling event featuring personal stories from three individuals touched by BRCA mutations, which all spoke to the promising future that research will provide for future patients and the newly BRCA-positive population. 

Basser Center Executive Director Susan Domchek, MD, joins KJZZ's The Show for an episode devoted to genetic testing, preventative surgery, and raising awareness of hereditary breast cancer.

Basser Young Leadership Council member Suzanne Zupello recently penned this personal piece on the importance of support communities for those with BRCA mutations for The Lily.

Basser Executive Director, Susan Domchek, MD, explains the recently began BRCA Founder Outreach Study (BFOR) with the Cleveland Jewish News.

Basser Executive Director, Susan Domchek, MD, discusses the challenges of treating pancreatic cancer, the role of BRCA mutations in malignancies other than breast or ovarian cancers, and the broader role of PARP inhibitors for this patient population.

Rates of inherited mutations in genes other than BRCA are twice as high in breast cancer patients who have had a second primary cancer – including, in some cases, different types of breast cancer – compared to patients who have only had a single breast cancer. 

A targeted therapy that has shown its power in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

Basser founders Mindy and Jon Gray are featured in a Bloomberg Markets article profiling people in finance who have defined their philanthropy early in their careers.

Forbes spoke with Susan Domchek, MD, Executive Director of the Basser Center, about how a woman with advanced breast cancer might choose among treatment options, and the latest data available on the effectiveness and safety of PARP inhibitors.